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OBJECTIVE—Leptin therapy improves insulin sensitivity in
people with leptin deﬁciency, but it is not known whether it
improves insulin action in people who are not leptin deﬁcient.
The purpose of the current study was to determine whether
leptin treatment has weight loss–independent effects on insulin
action in obese subjects with type 2 diabetes.
RESEARCH DESIGN AND METHODS—We conducted a ran-
domized, placebo-controlled trial in obese subjects (BMI: 35.4 6
0.6 kg/m
2; mean 6 SE) with newly diagnosed type 2 diabetes.
Subjects were randomized to treatment with placebo (saline),
low-dose (30 mg/day), or high-dose (80 mg/day) recombinant
methionyl human (r-Met hu) leptin for 14 days. Multiorgan insulin
sensitivity before and after treatment was evaluated by using the
hyperinsulinemic-euglycemic clamp procedure in conjunction with
stable isotopically labeled tracer infusions to measure glucose,
glycerol, and fatty acid kinetics.
RESULTS—Low-dose and high-dose leptin treatment resulted in
a threefold (P , 0.01) and 150-fold (P , 0.001) increase in basal
plasma leptin concentrations, respectively. However, neither low-
dose nor high-dose therapy had an effect on insulin-mediated
suppression of glucose, glycerol, or palmitate rates of appearance
into plasma compared with placebo. In addition, leptin treatment
did not increase insulin-mediated stimulation of glucose disposal
compared with placebo (14.3 6 3.1, 18.4 6 3.6, 16.7 6 2.4 vs.
17.5 6 2.5, 20.7 6 3.0, 19.1 6 3.3 mmol/kg body wt/min before vs.
after treatment in the placebo, low-dose, and high-dose leptin
groups, respectively).
CONCLUSIONS—r-Met hu leptin does not have weight loss–
independent, clinically important effects on insulin sensitivity in
o b e s ep e o p l ew i t ht y p e2d i a b e t e s .Diabetes 60:1474–1477, 2011
D
ata from studies conducted in animal models
indicate that leptin has beneﬁcial effects on
insulin action on glucose metabolism (1–3).
Leptin also has profound metabolic effects in
people. Leptin deﬁciency is associated with increased
body weight and insulin resistance (4), and leptin re-
placement therapy improves insulin sensitivity in people
with congenital leptin deﬁciency and leptin deﬁciency as a
result of lipodystrophy or HIV-induced lipoatrophy (5–8).
In contrast, obesity is commonly associated with insulin
resistance despite high plasma leptin concentrations (9–11).
Moreover, obesity is associated with resistance to many
of the metabolic effects of leptin (12), which has led to
the notion that resistance to leptin is involved in the
pathogenesis of obesity-related insulin resistance. We hy-
pothesized that increasing plasma leptin concentrations
by exogenous leptin administration can improve insulin
sensitivity in obese, insulin-resistant subjects. Accord-
ingly, we conducted a randomized, placebo-controlled trial
(NCT01207934) to evaluate the effect of low-dose and high-
dose leptin treatment on insulin action on glucose pro-
duction, glucose uptake, and lipolysis (by using a two-stage
euglycemic-hyperinsulinemic clamp in conjunction with sta-
ble isotopically labeled tracer infusions) in obese subjects
with newly diagnosed type 2 diabetes.
RESEARCH DESIGN AND METHODS
Subjects. Eighteen sedentary obese subjects with newly diagnosed type 2
diabetes who were not being treated with diabetes medications were ran-
domized to one of three treatment groups: 1) placebo (saline; four men and two
women; age: 60 6 3 years; BMI: 36 6 1 kg/m
2;H b A 1c:7 . 86 0.3%; fasting
plasma glucose concentration: 8.0 6 0.4 mmol/L), 2) low-dose (30 mg/day)
recombinant methionyl human (r-Met hu) leptin (two men and four women;
age: 53 6 7 years; BMI: 35 6 1 kg/m
2; HbA1c: 8.2 6 0.4%; fasting plasma glu-
cose concentration: 8.5 6 0.6 mmol/L), or 3) high-dose (80 mg/day) r-Met hu
leptin (three men and three women; age: 54 6 4 years; BMI: 36 6 1 kg/m
2;
HbA1c: 7.8 6 0.3%; fasting plasma glucose concentration: 9.5 6 0.5 mmol/L).
None of the subjects smoked tobacco, were pregnant or lactating, had sig-
niﬁcant organ system dysfunction, or took medications known to affect
metabolism. All subjects provided written, informed consent before partici-
pating in the study, which was approved by the Human Studies Committee of
Washington University School of Medicine.
Experimental protocol
Body composition analyses and hyperinsulinemic-euglycemic clamp
procedure. Subjects were admitted to the Clinical Research Unit (CRU) in the
afternoon before the clamp procedure. Total body mass, fat mass, and fat-free
mass were determined by using dual-energy X-ray absorptiometry (Hologic
QDR 4500, Waltham, MA).
At0600hthenextmorning,afteranovernightfast,onecatheterwasinserted
into a forearm vein for infusion and a second catheter was inserted into a hand
vein, which was heated to 55°C by using a thermostatically controlled box, to
obtain arterialized blood samples. At 0700 h, a primed, continuous infusion of
[6,6-
2H2]glucose was started and maintained until the end of the study, 10.5 h
later. At 0900 h, a continuous infusion of [1-
13C]palmitate and a primed, con-
tinuous infusion of [1,1,2,3,3-
2H5]glycerol were started and maintained for 5 h
(until the end of stage 1 of the clamp). At 1030 h, a two-stage (3.5 h each)
euglycemic-hyperinsulinemic clamp was started. During stage 1 (3.5 to 7.0 h),
insulin was infused at a rate of 20 mU/m
2 body surface area (BSA)/min (ini-
tiated by 80 mU/m
2 BSA/min for 5 min and then 40 mU/m
2 BSA/min for 5 min).
During stage 2 (7.0 to 10.5 h), insulin was infused at a rate of 50 mU/m
2
BSA/min (initiated by 200 mU/m
2 BSA/min for 5 min and then 100 mU/m
2 BSA/min
for 5 min). These two insulin infusion rates were chosen to evaluate liver and
adipose tissue insulin sensitivity (low-dose insulin infusion to submaximally
suppress hepatic glucose production and lipolysis of adipose tissue triglycerides)
and skeletal muscle insulin sensitivity (high-dose insulin infusion to adequately
stimulate muscle glucose uptake). Euglycemia was maintained at a blood glu-
cose concentration of ;5.5 mmol/L by variable rate infusion of 20% dextrose
enriched to 2.5% with [6,6-
2H2]glucose. The infusion rates of [6,6-
2H2]glucose,
[1-
13C]palmitate, and [1,1,2,3,3-
2H5]glycerol were reduced by 50% during stage 1,
and the infusion rate of [6,6-
2H2]glucose was reduced to 25% during stage 2 to
account for changes in endogenous glucose production and lipolysis.
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BRIEF REPORTBlood samples to determine plasma leptin and insulin concentrations and
substrate (glucose, palmitate, and glycerol) tracer-to-tracee ratios (TTRs) were
obtained before beginning the tracer infusion and every 10 min during the ﬁnal
30 min of the basal period and stages 1 and 2 of the clamp.
Plasma insulin and leptin concentrations were measured by using radio-
immunoassay (Linco Research, St. Charles, MO). Plasma glucose, palmitate,
and glycerol TTRs were determined by using gas chromatography-mass
spectroscopy.
Substrate rate of appearance (Ra) in plasma was calculated by dividing the
substrate tracer infusion rate by the average plasma substrate TTR. Endoge-
nous glucose production rate during the clamp procedure was calculated by
subtracting the exogenous glucose infusion rate from glucose Ra; glucose Rd
was calculated as the sum of endogenous glucose Ra and the rate of infused
glucose. Hepatic insulin sensitivity was assessed by using the hepatic insulin
sensitivity index, calculated as the product of basal endogenous glucose Ra
and plasma insulin concentration (13).
Intervention. After completion of the clamp procedure, subjects were ran-
domized to treatment with subcutaneous low-dose r-Met hu leptin (15-mg bid),
high-dose r-Met hu leptin (40-mg bid), or placebo (saline, 2-mL bid) for 14 days,
given by a research nurse during twice-daily home visits. The low dose was
intended to provide a modest (;threefold) increase in plasma leptin con-
centrations, whereas the high dose was intended to provide a pharmacological
exposure (;200-fold above baseline). Subjects were instructed to maintain
their usual dietary and physical activity habits and were weighed daily by the
research nurse. An increase in dietary intake was encouraged in any subject
who demonstrated a trend toward a decrease in body weight. On day 14 of
treatment, subjects were readmitted to the CRU, where the body composition
analyses and the clamp procedure were repeated. The ﬁnal doses of treatment
were given in the evening before the study.
Statistical analyses and sample size considerations. ANOVA with re-
peatedmeasureswasusedtocomparebetween(placebovs.low-doseandhigh-
dose leptin) and within (before vs. after treatment) group differences. Tukey
post hoc procedure was used if a signiﬁcant main effect was found. A P value
of # 0.05 was considered statistically signiﬁcant. Based on our own data
evaluating the reproducibility of the effect of insulin on glucose and fatty acid
kinetics during a euglycemic-hyperinsulinemic clamp in obese, insulin-resistant
subjects (14), we estimated that six subjects in each group would allow us
to detect a 25, 30, and 35% between-group difference in insulin-mediated
effects of glucose Ra, palmitate Ra, and glucose Rd, respectively, at the 0.05
a-level and a b-value of 0.20 (i.e., 80% power).
RESULTS
Body composition and plasma leptin. Baseline body
weight and body composition were similar between groups,
and body weight and body composition did not change in
any group after 2 weeks of treatment (Table 1). Plasma
leptin concentrations were not different between groups
before intervention. Plasma leptin remained unchanged
in the placebo group and increased by ;threefold and
;150-fold, respectively, in the low-dose and high-dose lep-
tin treatment groups (Table 1).
Substrate kinetics and insulin sensitivity. There were
no differences between groups in basal plasma insulin
concentrations, the hepatic insulin sensitivity index, and
basal substrate kinetics before and after placebo or leptin
treatment (Table 2). Plasma insulin concentrations and
substrate kinetics during the clamp procedure were also
not different between groups before and after placebo or
either dose of leptin treatment (Table 2). Plasma insulin
concentration increased from ;17 mU/L during basal
conditions to ;35 mU/L during stage 1 and to ;85 mU/L
during stage 2 both before and after 14 days of therapy.
Insulin-mediated suppression of endogenous glucose Ra
(;60 and ;80% decrease during stages 1 and 2, respec-
tively) and insulin-mediated increase in glucose Rd (;75%
increase during stage 2) was not different between groups
before and after placebo or either dose of leptin treatment.
Palmitate and glycerol Ra decreased by ;50 and ;35%,
respectively, during stage 1 of the clamp procedure and
were not different between groups before and after pla-
cebo or either dose of leptin treatment.
DISCUSSION
Leptin is an important regulator of insulin action; both
leptin deﬁciency and leptin resistance are associated with
insulin-resistant glucose metabolism (4,12). Furthermore,
leptin replacement improves insulin sensitivity in subjects
with leptin deﬁciency (5–8). Part of the beneﬁcial effect
of leptin replacement therapy could be a result of reduc-
tions in body weight in both leptin-deﬁcient rodents and
rodents with high-fat diet–induced obesity (3,11,15). How-
ever, leptin therapy increases insulin sensitivity in the ab-
sence of a signiﬁcant decrease in body weight or causes
a greater reduction in blood glucose concentration after
leptin-induced weight loss than after weight loss induced
by pair-feeding alone in wild-type and leptin-deﬁcient ro-
dent models (1,2,16) and improves insulin sensitivity in
leptin-deﬁcient subjects, even in the absence of signiﬁcant
changes in body weight (7,8,17). In contrast, our data
demonstrate that increasing leptin availability above nor-
mal plasma concentrations by treatment with r-Met hu
leptin does not have weight-loss–independent, clinically
important effects on insulin sensitivity in obese people
with type 2 diabetes. These results are consistent with data
from previous leptin weight loss trials, which found that
8–12 weeks of leptin therapy and a low-calorie diet did not
cause a greater change in plasma glucose or insulin con-
centrations than placebo therapy and a low-calorie diet
(18,19).
The reason(s) for the discrepancy in results from our
study and those conducted in leptin-deﬁcient subjects and
rodent obesity models is unclear. We studied only subjects
TABLE 1
Body composition and plasma leptin concentrations before and after placebo and leptin treatment
Placebo
Leptin
Low dose (30 mg/day) High dose (80 mg/day)
Before After Before After Before After
BMI (kg/m
2)3 6 6 13 6 6 13 5 6 13 5 6 13 6 6 13 6 6 1
Total body mass (kg) 108 6 4 108 6 49 3 6 69 2 6 6 106 6 5 105 6 5
Fat-free mass (kg) 64 6 46 4 6 45 8 6 65 7 6 66 4 6 56 4 6 5
Fat mass (kg) 44 6 34 4 6 33 5 6 33 6 6 34 2 6 44 2 6 4
Fat mass (% total body) 41 6 34 1 6 33 8 6 33 9 6 34 0 6 44 0 6 4
Plasma leptin (mg/L) 27 6 72 5 6 52 4 6 87 6 6 19* 35 6 10 5,024 6 500†
Values are means 6 SE. *Value signiﬁcantly different from corresponding value before, P # 0.05. †Value signiﬁcantly different from corre-
sponding value before, P , 0.001.
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type 2 diabetes and used sensitive measures to evaluate
insulin sensitivity in vivo to increase our ability to detect
an effect of leptin therapy on insulin action. Furthermore,
we gave low and high doses of r-Met hu leptin to our
subjects to ensure adequate plasma leptin concentrations
were achieved and to evaluate potential dose-dependent
effects. It is unlikely that the 2-week intervention in our
study was not long enough to affect insulin action, because
leptin administration alters glucose metabolism within
several hours in rodents (11) and the beneﬁcial metabolic
effects of leptin replacement therapy in subjects with
leptin deﬁciency occur within 1 week of treatment (20). In
addition, current treatment strategies in obese insulin-
resistant subjects, such as weight loss and pharmacother-
apy, demonstrate improved insulin sensitivity can occur
within days (13,21,22). Therefore, our data demonstrate
that leptin treatment has different metabolic effects in
subjects with leptin deﬁciency (who have almost no body
fat) than in obese subjects (who have high plasma leptin
concentrations and large amounts of body fat). However,
we cannot exclude the possibility that leptin treatment
would affect insulin action in overweight or obese subjects
who have a lower BMI than our cohort.
In addition, our results demonstrate that leptin does not
worsen insulin sensitivity, which has been suggested be-
cause of data obtained from studies conducted in obese
people and isolated adipocytes. At any given BMI, in-
creased plasma leptin concentration is associated with
greater insulin resistance (9,11), and withdrawal of chronic
leptin therapy in leptin-deﬁcient subjects improves insulin
sensitivity (23). Furthermore, large doses of leptin decrease
insulin signaling and metabolic actions of insulin in isolated
rat adipocytes (24,25). In our study, however, even re-
markably high plasma leptin concentrations did not cause
insulin resistance.
Although our study was conducted in a small number of
subjects, it is unlikely we missed an important therapeutic
effect of leptin as a result of inadequate statistical power,
because there was not even a trend in leptin-induced
changes in substrate kinetics with either dose of leptin
therapy compared with placebo. In contrast, current treat-
ment strategies for insulin resistance, such as weight loss
and pharmacotherapy, improve insulin-mediated glucose
uptake by ;25% or more (13,26,27).
In summary, we found that short-term treatment with
either low-dose or high-dose r-Met hu leptin did not im-
prove liver, skeletal muscle, or adipose tissue insulin sen-
sitivity in weight stable, obese subjects with type 2 diabetes.
The absence of a therapeutic effect of leptin in our study,
within the context of the observed beneﬁcial effects of
leptin replacement therapy in subjects with leptin de-
ﬁciency (4,7,8,12), suggests that a small amount of leptin
is important for normal insulin action, but increasing leptin
availability above normal plasma concentrations does not
have weight loss–independent effects on insulin action.
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Insulin (mU/L)
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